Merus N.V. Common Shares
N/A
USD
N/A
N/A
...
Chart
Financials
Description
MRUS Company Description
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.
MRUS Stock Smart Score
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?
Sign Up to view MRUS Smart Score
Score Breakdown
MRUS Company Description
Show More
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others. Show Less
All
Government
Consumer Interest
SEC Filings
ESG/Other
Recent trades of MRUS by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by MRUS's directors and management
Government lobbying spending instances
U.S. Patents
New patents grants
Government Contracts
Federal grants, loans, and purchases
Twitter
Followers on MRUS's company Twitter account
WallStreetBets
Number of mentions of MRUS in WallStreetBets Daily Discussion
MRUS News
Recent insights relating to MRUS
CNBC Recommendations
Recent picks made for MRUS stock on CNBC
Top ETF Holders
ETFs with the largest estimated holdings in MRUS
Corporate Flights
Flights by private jets registered to MRUS
Our Analysis